Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFREE
2024-518018-22-00Phase 3Authorised
- Sponsor
- CHU de Nantes
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rifampicin in staphylococcal prosthetic valve endocarditis and endocarditis (IE) (2 arms), sponsored by CHU de Nantes. Primary endpoint: All-cause mortality rate at 6 months post randomization. Planned start Aug 2025; status: authorised.
02
Drugs
rifampicin
03
Conditions
staphylococcal prosthetic valve endocarditisendocarditis (IE)
Beyond the preview
Go deeper on 2024-518018-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518018-22-00.